Hypocalcaemia and secondary hyperparathyroidism in institutionalised mentally-retarded patients receiving anticonvulsant drugs: a survey of 292 patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced* / Q000473:pathology; D006996:Hypocalcemia / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging; D008607:Intellectual Disability / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000139:chemically induced; D010024:Osteoporosis / Q000139:chemically induced; D010281:Parathyroid Hormone / Q000097:blood; D010634:Phenobarbital / Q000008:administration & dosage / Q000009:adverse effects; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects; D011324:Primidone / Q000008:administration & dosage / Q000009:adverse effects; D011859:Radiography
D000927:Anticonvulsants; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D011324:Primidone; D010672:Phenytoin; D010634:Phenobarbital